CO2018010357A2 - Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas - Google Patents

Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Info

Publication number
CO2018010357A2
CO2018010357A2 CONC2018/0010357A CO2018010357A CO2018010357A2 CO 2018010357 A2 CO2018010357 A2 CO 2018010357A2 CO 2018010357 A CO2018010357 A CO 2018010357A CO 2018010357 A2 CO2018010357 A2 CO 2018010357A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
alphaviruses
stabilize
living
Prior art date
Application number
CONC2018/0010357A
Other languages
English (en)
Inventor
Jill Ann Livengood
Timothy Duane Powell
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CO2018010357A2 publication Critical patent/CO2018010357A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las modalidades aquí se refieren a las composiciones y métodos para estabilizar los alfavirus vivos. Otras modalidades se refieren a composiciones y métodos para reducir la degradación de alfavirus atenuados vivos. Ciertas modalidades se refieren a proporcionar una composición estabilizante mientras se reduce la reacción inmune en un sujeto a excipientes que estabilizan los alfavirus vivos proporcionando formulaciones mejoradas. Todavía otras modalidades se refieren a usos de composiciones descritas aquí en kits para aplicaciones portátiles y métodos en donde las composiciones reducen la degradación de los alfavirus vivos.
CONC2018/0010357A 2016-03-31 2018-09-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas CO2018010357A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (1)

Publication Number Publication Date
CO2018010357A2 true CO2018010357A2 (es) 2019-05-21

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010357A CO2018010357A2 (es) 2016-03-31 2018-09-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Country Status (19)

Country Link
US (2) US10632184B2 (es)
EP (1) EP3436063A1 (es)
JP (1) JP2019513138A (es)
KR (1) KR20180135912A (es)
CN (1) CN109069614A (es)
AU (1) AU2017241590A1 (es)
BR (1) BR112018069035A2 (es)
CA (1) CA3019529A1 (es)
CO (1) CO2018010357A2 (es)
CR (1) CR20180456A (es)
DO (1) DOP2018000211A (es)
EC (1) ECSP18081486A (es)
MX (1) MX2018011837A (es)
NI (1) NI201800096A (es)
PE (1) PE20190149A1 (es)
PH (1) PH12018502119A1 (es)
SG (1) SG11201808458QA (es)
SV (1) SV2018005747A (es)
WO (1) WO2017172643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
BR112022002082A2 (pt) * 2019-08-09 2022-04-12 Valneva Se Formulações de vacina contra o chikungunya
MX2022000948A (es) * 2019-08-09 2022-02-14 Valneva Se Vacuna de una sola dosis contra el virus chikunguña.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MY178476A (en) * 2013-03-14 2020-10-14 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
US10632184B2 (en) 2020-04-28
EP3436063A1 (en) 2019-02-06
CR20180456A (es) 2019-01-09
AU2017241590A1 (en) 2018-10-11
DOP2018000211A (es) 2018-12-31
SG11201808458QA (en) 2018-10-30
US20200306361A1 (en) 2020-10-01
PH12018502119A1 (en) 2019-07-15
PE20190149A1 (es) 2019-01-22
JP2019513138A (ja) 2019-05-23
KR20180135912A (ko) 2018-12-21
CN109069614A (zh) 2018-12-21
CA3019529A1 (en) 2017-10-05
NI201800096A (es) 2019-02-01
SV2018005747A (es) 2019-03-28
US20190111124A1 (en) 2019-04-18
BR112018069035A2 (pt) 2019-01-29
WO2017172643A1 (en) 2017-10-05
MX2018011837A (es) 2019-02-13
ECSP18081486A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
CL2019000473A1 (es) Compuestos de pirrolizina sustituida y usos de los mismos.
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2018000162A1 (es) Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2015002675A1 (es) Composiciones de arnm de cftr y métodos y usos relacionados
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CO2018010357A2 (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
BR112017002354A2 (pt) artigo absorvente extensível
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
MX2019000177A (es) Formulaciones de anticuerpos.
AR105894A1 (es) Composición para aplicación tópica que comprende dimetil isosorbida, un poliol, y un antioxidante fenólico o polifenólico
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
UY35823A (es) Profármacos de antagonista de nmda
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
CL2020000586A1 (es) Moduladores de la expresión de enac.
IN2014DE02625A (es)